Herpes Zoster Market Segmentation:
Route of Administration Segment Analysis
Based on the route of administration, the oral segment is expected to account for more than 83.1% herpes zoster market share by the end of 2035. The driving factor of this segment majorly lies in the growing demand and popularity for pain management drugs. The effectiveness of antiviral drugs has also accumulated the interest of service providers to incorporate them as a part of oral therapeutics in their treatment process. New drugs are now being introduced to expand the product range of this segment. For instance, in July 2022, a research report was published, introducing a new treatment, TELTAB for severely painful Herpes infection. This painless injection method is dedicated to curing severely painful cases.
Treatment and Prevention Segment Analysis
In terms of treatment and prevention, the antiviral medications segment is expected to dominate the herpes zoster market with a significant share by the end of 2035. Being a crucial part of the mainstream treatment process, these drugs help reduce the severity and duration of the infection. The proven effectiveness of such medication has inspired companies and research institutions to explore more possibilities of application in this segment. For instance, in October 2024, NYU Langone revealed the results of the eight-year Zoster Eye Disease Study (ZEDS) on anti-viral drugs at the annual AAO meeting in Chicago. The report established the efficacy of a low dose of valacyclovir over a year, showcasing a 26% risk reduction of new or worsening keratitis or iritis at 18 months.
Our in-depth analysis of the global herpes zoster market includes the following segments:
|
Route of Administration |
|
|
Treatment and Prevention |
|
|
End user |
|
